Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers microencapsulation solutions; and human grade choline nutrients and mineral amino acid chelated products for wellness applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. This segment also sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was incorporated in 1967 and is headquartered in New Hampton, New York.
IPO Year:
Exchange: NASDAQ
Website: balchem.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/8/2022 | $170.00 → $155.00 | Buy | HC Wainwright & Co. |
| 2/22/2022 | $175.00 | Neutral → Buy | Sidoti |
| 1/10/2022 | $160.00 → $170.00 | Buy | HC Wainwright & Co. |
| 11/29/2021 | $175.00 | Buy → Neutral | Sidoti |
| 8/2/2021 | $140.00 → $145.00 | Overweight → Equal-Weight | Stephens & Co. |
| 8/2/2021 | $145.00 → $160.00 | Buy | HC Wainwright & Co. |
10-Q - BALCHEM CORP (0000009326) (Filer)
8-K - BALCHEM CORP (0000009326) (Filer)
11-K - BALCHEM CORP (0000009326) (Filer)
8-K - BALCHEM CORP (0000009326) (Filer)
SCHEDULE 13G/A - BALCHEM CORP (0000009326) (Subject)
DEFA14A - BALCHEM CORP (0000009326) (Filer)
DEF 14A - BALCHEM CORP (0000009326) (Filer)
10-Q - BALCHEM CORP (0000009326) (Filer)
8-K - BALCHEM CORP (0000009326) (Filer)
8-K - BALCHEM CORP (0000009326) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - BALCHEM CORP (0000009326) (Issuer)
4/A - BALCHEM CORP (0000009326) (Issuer)
4/A - BALCHEM CORP (0000009326) (Issuer)
4/A - BALCHEM CORP (0000009326) (Issuer)
4/A - BALCHEM CORP (0000009326) (Issuer)
4/A - BALCHEM CORP (0000009326) (Issuer)
4/A - BALCHEM CORP (0000009326) (Issuer)
4/A - BALCHEM CORP (0000009326) (Issuer)
4/A - BALCHEM CORP (0000009326) (Issuer)
4/A - BALCHEM CORP (0000009326) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $155.00 from $170.00 previously
Sidoti upgraded Balchem from Neutral to Buy and set a new price target of $175.00
HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $170.00 from $160.00 previously
Sidoti downgraded Balchem from Buy to Neutral and set a new price target of $175.00
Stephens & Co. downgraded Balchem from Overweight to Equal-Weight and set a new price target of $145.00 from $140.00 previously
HC Wainwright & Co. upgraded Balchem from to Buy and set a new price target of $160.00 from $145.00 previously
HC Wainwright reiterated coverage of Balchem with a rating of Buy and set a new price target of $145.00 from $126.00 previously
Stephens upgraded Balchem from Equal Weight to Overweight and set a new price target of $140.00 from $100.00 previously
Stephens & Co. upgraded Balchem from Equal-Weight to Overweight and set a new price target of $140.00 from $100.00 previously
Stephens upgraded Balchem from Equal-Weight to Overweight
Live Leadership Updates
BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an
Fastest customizable press release news feed in the world
MONTVALE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal second quarter ended June 30, 2025. For the quarter, the Company reported net sales of $255.5 million, net earnings of $38.3 million, adjusted EBITDA(a) of $69.2 million, and free cash flow(a) of $40.7 million. Ted Harris, Chairman, President and CEO of Balchem said, "The second quarter was another excellent quarter for Balchem. We delivered record financial results, driven by strong growth in all three of our reporting segments, while continuing to make good progress on our strategic growth initiatives." Second Quarter 2025 Financial Highlights: Recor
MONTVALE, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Thursday, July 31, 2025, at 11:00 AM Eastern Time (ET) to review second quarter 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Second quarter results will be published prior to the market opening on Thursday, July 31, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. To improve the quality of both the live and recorded audio for our conference calls, we have ch
MONTVALE, N.J., June 26, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at the CJS Annual New Ideas Summer Conference on July 10, 2025. Ted Harris, Chairman of the Board, Chief Executive Officer, and President, Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations will present at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest qual
MONTVALE, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at the Wells Fargo Industrials and Materials Conference on June 11, 2025. Ted Harris, Chairman of the Board, Chief Executive Officer, and President, Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations will present at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the fi
MONTVALE, N.J., May 21, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the dbAccess Global Consumer Conference on June 4, 2025. Ted Harris, Chairman of the Board, Chief Executive Officer, and President and Martin Bengtsson, Chief Financial Officer will participate at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest quality products for a range of industries worldwide. The
MONTVALE, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal first quarter ended March 31, 2025. For the quarter, the Company reported net sales of $250.5 million, net earnings of $37.1 million, adjusted EBITDA(a) of $66.3 million, and free cash flow(a) of $31.0 million. Ted Harris, Chairman, President and CEO of Balchem said, "The first quarter was an excellent start to the year for Balchem, with sales and earnings growth in all three segments. We delivered record net sales and adjusted EBITDA, strong net earnings, and solid first quarter cash flows." First Quarter 2025 Financial Highlights: Record net sales o
MONTVALE, N.J., April 22, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today published its 2024 Sustainability Report. Our Sustainability Report outlines the Company's ongoing commitment to providing employees, customers, shareholders, and the communities in which we operate with information on Balchem's sustainability initiatives, guided by our core values and our vision of making the world a healthier place. "I am pleased with the progress Balchem continues to make in advancing our broad-based sustainability efforts, as detailed in our 2024 Sustainability Report." said Ted Harris, Chairman, President, and Chief Executive Officer. "Our performance, notably on our 2030 goal
MONTVALE, N.J., April 11, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Thursday, April 24, 2025, at 11:00 AM Eastern Time (ET) to review first quarter 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. First quarter results will be published prior to the market opening on Thursday, April 24, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341),
MONTVALE, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the BNP Paribas Exane 13th Consumer Ingredients Conference on March 11, 2025. Ted Harris, Chairman of the Board, Chief Executive Officer, and President, Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations will participate at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solu
MONTVALE, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal fourth quarter ended December 31, 2024. For the quarter, the Company reported net sales of $240.0 million, net earnings of $33.6 million, adjusted EBITDA(a) of $62.8 million, and free cash flow(a) of $39.8 million. Ted Harris, Chairman, President, and CEO of Balchem said, "The fourth quarter capped off another very strong year for Balchem. We delivered record fourth quarter net sales and adjusted EBITDA, with top and bottom line year over year growth in each of our three segments." Fourth Quarter 2024 Financial Highlights:
Live finance-specific insights
MONTVALE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal second quarter ended June 30, 2025. For the quarter, the Company reported net sales of $255.5 million, net earnings of $38.3 million, adjusted EBITDA(a) of $69.2 million, and free cash flow(a) of $40.7 million. Ted Harris, Chairman, President and CEO of Balchem said, "The second quarter was another excellent quarter for Balchem. We delivered record financial results, driven by strong growth in all three of our reporting segments, while continuing to make good progress on our strategic growth initiatives." Second Quarter 2025 Financial Highlights: Recor
MONTVALE, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Thursday, July 31, 2025, at 11:00 AM Eastern Time (ET) to review second quarter 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Second quarter results will be published prior to the market opening on Thursday, July 31, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. To improve the quality of both the live and recorded audio for our conference calls, we have ch
MONTVALE, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal first quarter ended March 31, 2025. For the quarter, the Company reported net sales of $250.5 million, net earnings of $37.1 million, adjusted EBITDA(a) of $66.3 million, and free cash flow(a) of $31.0 million. Ted Harris, Chairman, President and CEO of Balchem said, "The first quarter was an excellent start to the year for Balchem, with sales and earnings growth in all three segments. We delivered record net sales and adjusted EBITDA, strong net earnings, and solid first quarter cash flows." First Quarter 2025 Financial Highlights: Record net sales o
MONTVALE, N.J., April 11, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Thursday, April 24, 2025, at 11:00 AM Eastern Time (ET) to review first quarter 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. First quarter results will be published prior to the market opening on Thursday, April 24, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341),
MONTVALE, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal fourth quarter ended December 31, 2024. For the quarter, the Company reported net sales of $240.0 million, net earnings of $33.6 million, adjusted EBITDA(a) of $62.8 million, and free cash flow(a) of $39.8 million. Ted Harris, Chairman, President, and CEO of Balchem said, "The fourth quarter capped off another very strong year for Balchem. We delivered record fourth quarter net sales and adjusted EBITDA, with top and bottom line year over year growth in each of our three segments." Fourth Quarter 2024 Financial Highlights:
MONTVALE, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, February 21, 2025, at 11:00 AM Eastern Time (ET) to review fourth quarter and full year 2024 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Fourth quarter and full year results will be published prior to the market opening on Friday, February 21, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-87
MONTVALE, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that on December 9, 2024, its Board of Directors declared a dividend on its shares of common stock equal to $0.87 per share on the Company's issued and outstanding Common Stock, to be payable on January 17, 2025 to stockholders of record at the close of business on December 26, 2024. This dividend represents an 10.1% increase over last year's annual dividend. Ted Harris, Balchem's Chairman, President and CEO, said, "Balchem has a long-standing commitment to an annual dividend and we are pleased to announce the continuation of that commitment. This dividend represents the sixteenth consecuti
MONTVALE, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal third quarter ended September 30, 2024. For the quarter, the Company reported net sales of $239.9 million, net earnings of $33.8 million, adjusted EBITDA(a) of $64.4 million, and free cash flow(a) of $42.2 million. Ted Harris, Chairman, President and CEO of Balchem said, "We delivered strong third quarter financials with solid revenue growth and record earnings from operations and adjusted EBITDA. We continue to see excellent performance in our Human Nutrition and Health and Specialty Products segments, both delivering strong sales and earnings g
MONTVALE, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, October 25, 2024, at 11:00 AM Eastern Time (ET) to review third quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Third quarter results will be published prior to the market opening on Friday, October 25, 2024. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341), five m
MONTVALE, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal second quarter ended June 30, 2024. The Company reported quarterly net sales of $234.1 million, quarterly net earnings of $32.1 million, adjusted EBITDA(a) of $62.3 million, and free cash flow(a) of $38.4 million. Ted Harris, Chairman, President and CEO of Balchem said, "We delivered solid second quarter financials with record earnings from operations and adjusted EBITDA. I am particularly pleased with the excellent performance in our Human Nutrition and Health and Specialty Products segments, both delivering strong sales and earnings growth." Second Qu
This live feed shows all institutional transactions in real time.
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G - BALCHEM CORP (0000009326) (Subject)